Table 1 Baseline characteristics. All patients who received at least one dose of either maraviroc or placebo are included.
From: CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection
Characteristic | Matching placebo, b.i.d. (n = 24) | Maraviroc, 150 mg b.i.d. (n = 23) | p Value |
|---|---|---|---|
Age, years | Â | Â | Â |
Mean (SD) | 49.8 (10.0) | 49.0 (9.1) | Â |
Range | 29.1 to 70.9 | 33.7 to 68.2 | 0.772 |
Sex | Â | Â | Â |
Male (%) | 24 (100.0) | 22 (95.7) | Â |
Female (%) | 0 (0.0) | 1 (4.3) | 0.982 |
Ethnicity, number (%) | Â | Â | Â |
Caucasian | 19 (79.2) | 18 (78.3) | Â |
Hispanic | 1 (4.2) | 3 (13.0) | Â |
Black | 3 (12.5) | 1 (4.4) | Â |
Asian | 1 (4.2) | 0 (0.0) | Â |
Other | 0 (0.0) | 1 (4.4) | 0.405 |
HIV-1 RNA, copies/mL plasma | Â | Â | Â |
Mean | <50 | <50 | Â |
Range | <50 | <50 | 1.000 |
Nadir CD4 count, cells/µL blood |  |  |  |
Mean (IQR) | 147 (76 to 242) | 83 (45 to 189) | Â |
Range | 5 to 677 | 5 to 274 | 0.170 |
CD4 count, cells/µL blood |  |  |  |
Mean (IQR) | 489 (342 to 705) | 523 (351 to 576) | Â |
Range | 213 to 1493 | 228 to 798 | 0.717 |
CD8 count, cells/µL blood |  |  |  |
Mean (IQR) | 707 (505 to 923) | 809 (726 to 1110) | Â |
Range | 244 to 2032 | 465 to 1362 | 0.070 |